Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
in the year and is preparing for an NDA submission the following year after recently raising capital. Vidofludimus calcium is positioned as a dual-mechanism oral therapy—selective DHODH inhibition (avoiding teriflunomide's reported off-target kinase activity) plus Nurr1 activation—which the company says could provide both anti-inflammatory effects and direct neuroprotection that may slow disability progression/PIRA. Management highlights a differentiated safety profile (liver enzyme elevations comparable to placebo and a much shorter half-life of ~30 hours versus teriflunomide), and cites exploratory CALLIPER Phase 2 results showing a 24% reduction in 24-week confirmed disability progression overall and 31% in PPMS, prompting a planned confirmatory Phase 3 in PPMS. Interested in Immunic, Inc.? Here are five stocks we like better. Immunic (NASDAQ:IMUX) executives outlined what they described as a “transformative” 2026, with pivotal data expected late in the year for the company
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]Yahoo! Finance
- Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus CalciumPR Newswire
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Analyst Actions
- 2/9/26 - HC Wainwright
IMUX
Sec Filings
- 3/4/26 - Form SCHEDULE
- 3/4/26 - Form D
- 3/2/26 - Form DEF
- IMUX's page on the SEC website